SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-21-000050
Filing Date
2021-06-03
Accepted
2021-06-03 08:08:12
Documents
14
Period of Report
2021-06-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20210603.htm   iXBRL 8-K 40167
2 EX-99.1 a2021-06x03xxoystxxetfgene.htm EX-99.1 30854
6 image.jpg GRAPHIC 5960
  Complete submission text file 0001720725-21-000050.txt   226816

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20210603.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20210603_lab.xml EX-101.LAB 26052
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20210603_pre.xml EX-101.PRE 13751
7 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20210603_htm.xml XML 11481
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 21991255
SIC: 2836 Biological Products, (No Diagnostic Substances)